CH682803A5 - Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis - Google Patents
Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis Download PDFInfo
- Publication number
- CH682803A5 CH682803A5 CH41393A CH41393A CH682803A5 CH 682803 A5 CH682803 A5 CH 682803A5 CH 41393 A CH41393 A CH 41393A CH 41393 A CH41393 A CH 41393A CH 682803 A5 CH682803 A5 CH 682803A5
- Authority
- CH
- Switzerland
- Prior art keywords
- bronchial asthma
- compsn
- panthenol
- diseases
- osteoarthritis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
1 1
CH 682 803 A5 CH 682 803 A5
2 2nd
Beschreibung description
Das Acetyl-Coenzym A (Acetyl-CoA) stellt eine biologisch aktive Form der Pantothensäure dar (Fig. 1). Coenzym A wird in der Zelle aus Pantothensäure gebildet und nimmt eine zentrale Stellung im Intermediärstoffwechsel ein (Schema 1). Es bewirkt in acetylierter Form (Acetyl-Coenzym A) die Synthese von Fettsäuren, Cholesterin und Cortico-steroiden. Pantothensäure-Mangel zieht eine verminderte endogene Corticosteroid-Produktion nach sich. The acetyl-coenzyme A (acetyl-CoA) is a biologically active form of pantothenic acid (Fig. 1). Coenzyme A is formed in the cell from pantothenic acid and plays a central role in the intermediate metabolism (Scheme 1). In acetylated form (acetyl-coenzyme A) it effects the synthesis of fatty acids, cholesterol and cortico-steroids. Pantothenic acid deficiency leads to reduced endogenous corticosteroid production.
Pantothensäure wird in Form ihrer Salze und Derivate (Panthenol, Pantethein, Na- oder Kalziumpan-tothenat) verabreicht, die nach oraler Gabe dieselben physiologischen Wirkungen wie Pantothensäure besitzen. Pantothenic acid is administered in the form of its salts and derivatives (panthenol, pantethein, sodium or calcium pantothenate), which after oral administration have the same physiological effects as pantothenic acid.
Pantothensäure-Entzug bei der Ratte bewirkte, dass Pantothenic acid withdrawal in the rat caused that
- der Cholesterin-Gehait der Nebennieren (Cholesterin ist die Vorstufe zu Cortisol) bei den Panto-thensäure-Mangel-Tieren um 76% sank (Fig. 2) the cholesterol content of the adrenal glands (cholesterol is the precursor to cortisol) decreased by 76% in the pantothenic acid-deficient animals (FIG. 2)
- die Mangeltiere nur etwa die Hälfte der ursprünglichen Corticosteroid-Menge synthetisierten (Fig. 3) the deficient animals synthesized only about half of the original amount of corticosteroid (FIG. 3)
- das Muster der ausgeschiedenen 17-Ketosteroide völlig verändert wurde (Fig. 3). - The pattern of the excreted 17-ketosteroids was completely changed (Fig. 3).
Hohe Dosen von Pantothensäure stimulieren die Corticosteroid-Synthese bei der Ratte. High doses of pantothenic acid stimulate corticosteroid synthesis in the rat.
- Fig. 4 zeigt, dass die intramuskuläre Gabe von Natriumpantothenat innerhalb von sechs Stunden eine beinahe 100%-ige Erhöhung des Corticoste-roid-Gehaltes in den Nebennieren bewirkte. 4 shows that intramuscular administration of sodium pantothenate brought about an almost 100% increase in the corticosteroid content in the adrenal glands within six hours.
Hohe Dosen von Pantothensäure stimulieren die endogene Corticosteroid-Synthese auch beim Menschen: High doses of pantothenic acid also stimulate endogenous corticosteroid synthesis in humans:
- Fig. 5 zeigt eine alters- und geschlechtsspezifische Abhängigkeit der Pantothensäure-induzierten Stimulierung der Corticosteroid-Synthese. 5 shows an age-specific and gender-specific dependency of pantothenic acid-induced stimulation of corticosteroid synthesis.
- Fig. 6 zeigt, dass die Plasmaspiegel von Cortisol und ACTH («âdrenosorticoîropic hormon») signifikant erhöht sind. Diese Erhöhung bleibt aber innerhalb der physiologischen Grenzen, d.h. hohe Dosen von Pantothensäure lösen keine unspezifischen, Stress-ähnliche Reaktionen aus. Befürchtungen, dass hohe Dosen von Pantothensäure-Derivaten eine Überproduktion an Steroiden bewirken könnten, sind völlig unbegründet. Eine negative Rückkopplung mit Cortisol als ACTH-Hemmer sorgt für Verhinderung der Überproduktion (Fig. 7). 6 shows that the plasma levels of cortisol and ACTH (“adrenosorticoîropic hormone”) are significantly increased. However, this increase remains within the physiological limits, i.e. high doses of pantothenic acid do not trigger unspecific, stress-like reactions. Fears that high doses of pantothenic acid derivatives could cause steroid overproduction are completely unfounded. Negative feedback with cortisol as an ACTH inhibitor prevents overproduction (FIG. 7).
- Patienten mit Neurodermitis erhielten Kalzium-Pantothenat (2 x 500 mg täglich). Nach vier Wochen Behandlung erhöhten sich die Blutspiegel von ACTH signifikant. - Patients with neurodermatitis received calcium pantothenate (2 x 500 mg daily). After four weeks of treatment, blood levels of ACTH increased significantly.
Klinische Untersuchungen haben gezeigt, dass die stimulierende Wirkung von Pantothensäure auf die Blutspiegel von ACTH und Cortisol, bei der Behandlung von Krankheiten, die mit Corticosteroiden therapierbar sind, anwendbar ist. Beispiele: Clinical studies have shown that the stimulating effect of pantothenic acid on the blood levels of ACTH and cortisol can be used in the treatment of diseases which can be treated with corticosteroids. Examples:
- Patienten mit Neurodermitis wurden mit 2 x 500 mg Kalziumpantothenat täglich behandelt. Der Juckreiz war innerhalb von einigen Wochen vollkommen verschwunden. Die anderen Symptome hatten sich in der Mehrheit der Fälle ebenfalls verbessert. Diese Studie zeigt, dass Kalziumpantothenat, verabreicht in Tablettenform täglich, in der Lage ist, die - Patients with neurodermatitis were treated with 2 x 500 mg calcium pantothenate daily. The itching was completely gone within a few weeks. The other symptoms had also improved in the majority of the cases. This study shows that calcium pantothenate, administered in tablet form daily, is capable of that
Symptome von Neurodermitis wesentlich zu verbessern und die Krankheit unter Kontrolle zu halten. Significantly improve symptoms of atopic dermatitis and keep the disease under control.
- Patienten mit Asthma bronchiale wurden mit 2 x 500 mg Kalziumpantothenat behandelt. Die Patienten blieben während der dreimonatigen Behandlung anfallsfrei. - Patients with bronchial asthma were treated with 2 x 500 mg calcium pantothenate. The patients remained seizure-free during the three-month treatment.
- Patienten mit chronischer Polyarthritis wurden mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In der Mehrheit der Fälle haben sich die Krankheitssymptome während der Behandlung kontinuierlich verbessert. - Patients with chronic polyarthritis were treated with calcium pantothenate (2 x 500 mg daily). In the majority of cases, the symptoms of the disease have improved continuously during treatment.
- Patienten mit Osteoarthrose wurden mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In der Mehrheit der Fälle haben sich die Krankheitssymptome kontinuierlich verbessert. - Patients with osteoarthritis were treated with calcium pantothenate (2 x 500 mg daily). In the majority of cases, the symptoms of the disease have improved continuously.
- Patienten mit Sportverletzungen wurden während zwei Wochen mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In den meisten Fällen haben sich die Symptome verbessert oder sind ganz verschwunden. - Patients with sports injuries were treated with calcium pantothenate (2 x 500 mg daily) for two weeks. In most cases the symptoms have improved or have disappeared completely.
- In mehreren Fällen wurde Kalziumpantothenat (500 mg täglich) prophylaktisch zur Verhinderung von Heuschnupfen mit Erfolg eingesetzt. - In several cases calcium pantothenate (500 mg daily) was used prophylactically to prevent hay fever.
- Patienten mit chronisch rezidivierenden Sinusitis maxillaris wurden während 6-10 Wochen mit Kalziumpantothenat (2 x 500 mg täglich) behandelt. In 70% der Fälle wurde eine wesentliche Verbesserung der Symptome festgestellt. - Patients with chronic recurrent maxillary sinusitis were treated with calcium pantothenate (2 x 500 mg daily) for 6-10 weeks. Significant improvement in symptoms was noted in 70% of cases.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH41393A CH682803A5 (en) | 1993-02-11 | 1993-02-11 | Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH41393A CH682803A5 (en) | 1993-02-11 | 1993-02-11 | Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
CH682803A5 true CH682803A5 (en) | 1993-11-30 |
Family
ID=4186467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH41393A CH682803A5 (en) | 1993-02-11 | 1993-02-11 | Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis |
Country Status (1)
Country | Link |
---|---|
CH (1) | CH682803A5 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019359A2 (en) * | 1999-09-16 | 2001-03-22 | Britannia Pharmaceuticals Limited | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
WO2009010707A1 (en) * | 2007-07-13 | 2009-01-22 | Prototype Bioforum Limited | Injectable pharmaceutical compositions containing panthenol |
-
1993
- 1993-02-11 CH CH41393A patent/CH682803A5/en not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001019359A2 (en) * | 1999-09-16 | 2001-03-22 | Britannia Pharmaceuticals Limited | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
GB2355930A (en) * | 1999-09-16 | 2001-05-09 | Britannia Pharmaceuticals Ltd | Injection of pantothenic acid for relief of pain in joints |
WO2001019359A3 (en) * | 1999-09-16 | 2002-10-03 | Britannia Pharmaceuticals Ltd | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease |
US8614249B2 (en) | 1999-09-16 | 2013-12-24 | Prototype Bioforum Ltd. | Medicaments containing pantothenic acid |
WO2009010707A1 (en) * | 2007-07-13 | 2009-01-22 | Prototype Bioforum Limited | Injectable pharmaceutical compositions containing panthenol |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69801047T2 (en) | NUTRITIONAL SUPPLEMENT | |
DE69629273T2 (en) | Compositions containing propionyl-L-carnitine and hydroxycitric acid or pantothenic acid | |
DE69814834T2 (en) | NUTRITIONAL COMPOSITION TO IMPROVE CELL ENERGY | |
US5240961A (en) | Method of treating reduced insulin-like growth factor and bone loss associated with aging | |
DE69420746T2 (en) | MEDICINES AGAINST STRESS, INTERFERENCE AND AGING AND METHOD FOR THE PRODUCTION THEREOF | |
DE60207877T2 (en) | Composition containing procyanidins for reducing appetite in mammals | |
EP0046167A1 (en) | Nutrient solution for complete extra-buccal feeding and for an enhanced production of energy, and manufacturing process | |
DE69820029T2 (en) | Combined composition consisting of L-carnitine or L-alkanoyl carnitine, a glycosaminoglycan and / or one of its components | |
US6436946B1 (en) | Xanthine-containing compositions for oral administration and uses related thereto | |
JPH05148200A (en) | Acyl-l-carnitine derivative for treatment of myopathy and nerve degeneration | |
DE60210488T2 (en) | USE OF HYDROXYLIC ACID AND SIMILAR COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS | |
DE60103055T2 (en) | NUTRITIONAL SUPPLEMENT FOR IMPROVING MUSCLE ENERGY METABOLISM, CONTAINING ALKANOYL-CARNITINE AND RIBOSE | |
DE3854121T2 (en) | MEDICINAL COMPOSITIONS FOR TREATING PSORIASIS. | |
CH682803A5 (en) | Use of panthenol, pantetheine or pantothenate, capable of stimulating endogeneous cortico-steroid biosynthesis - in compsn. for treating e.g. bronchial asthma, rheumatism, hay fever or osteoarthritis | |
DE69315162T2 (en) | Use of L-carnitine and acyl-L-carnitine for the treatment of patients suffering from AIDS-related syndromes and of asymptomatic HIV-seropositive patients | |
US5304574A (en) | Methods of treatment of clinical conditions using pantothenic acid | |
WO2012076680A1 (en) | Combination preparation for improving female fertility | |
US20030165585A1 (en) | Xanthine-containing compositions for oral administration and uses related thereto | |
EP1789026B1 (en) | Method for systemic bio-correction of an organism | |
RU2698396C1 (en) | Pharmaceutical composition for parenteral drop introduction | |
DE2429034A1 (en) | NUTRITIONAL LIQUID FOR PARENTERAL TRACKING | |
CARLSSON et al. | A comparative study on the mode of action of dihydrotachysterol and vitamin D on the calcium metabolism | |
DE69909395T2 (en) | COMPOSITION WITH KETANSERIN AND CARNITIN FOR TREATING CRPS | |
US6329358B1 (en) | Pharmaceutical composition suitable for stimulating the multiplication and growth of osteoblasts | |
DE3625459A1 (en) | Ubiquinone-containing pharmaceutical composition for oral administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |